BioNTech SE is charting a definitive course beyond its pandemic-era success, with a promising cancer therapy now on a clear path toward its first-ever oncology drug application. The company, bolstered by a massive cash reserve, is preparing to submit a Biologics License Application (BLA) to the U.S. FDA for its endometrial cancer candidate in 2026, a move that would mark a historic strategic milestone.
The candidate, an antibody-drug conjugate (ADC) named Trastuzumab Pamirtecan (BNT323), is being developed in partnership with Shanghai-based DualityBio. Recent Phase 2 data presented at the Society of Gynecologic Oncology’s annual meeting has provided the robust foundation for this planned filing. In a study of 73 patients with HER2-positive endometrial cancer who had previously been treated with checkpoint inhibitors, the therapy demonstrated an overall response rate of 49.3%. This stands in stark contrast to the approximately 15% response rate typically seen with chemotherapy in similar settings.
The drug’s efficacy extended beyond traditional benchmarks. Patients experienced a median progression-free survival of eight months, doubling the roughly four months seen with standard chemotherapy. The median duration of response was 10.3 months. A key differentiator is the therapy’s breadth: it showed activity across all levels of HER2 expression, including lower levels (IHC 1+ and 2+) where response rates were approximately 34% and 40%, respectively. This addresses a significant patient population currently without a targeted HER2 treatment option, unlike the approved competitor Enhertu, which is indicated only for patients with the highest HER2 expression (IHC 3+).
Wall Street has taken note of the progress. Bank of America’s BofA Securities raised its price target on BioNTech’s U.S.-listed shares to $130 from $128, maintaining a Buy rating. Analysts at Berenberg reiterated their Buy recommendation, while Morgan Stanley holds an “Overweight” rating with a $126 price target. The overall analyst sentiment remains constructive; of 18 covering analysts, 13 recommend buying the stock, with a consensus price target of $133.13. A dissenting voice comes from Leerink Partners, which downgraded the stock to “Market Perform” with a $113 target.
Should investors sell immediately? Or is it worth buying BioNTech?
Despite the clinical optimism, the stock’s recent performance has been muted. Shares recently traded at €83.20, down 1.25% on the day and remaining below the technically significant 200-day moving average of €88.15, despite a weekly gain of nearly 7%. The commercial opportunity for this specific second-line endometrial cancer indication is considered modest, with BofA noting it contributes only about $3 to its price target calculation.
The true value lies in the strategic pivot. A successful approval would establish BioNTech’s first commercial oncology product and build the necessary infrastructure for its broader cancer pipeline. The FDA has already granted the candidate both Fast Track and Breakthrough Therapy designations in 2023. Patient recruitment is ongoing for the confirmatory global Phase 3 trial, Fern-EC-01, which will directly compare the ADC to chemotherapy.
Financing this ambitious transition is not a concern. The company ended 2025 with a formidable liquidity reserve of approximately €17.2 billion. This war chest funded the April 2023 licensing deal with DualityBio, which included a $170 million upfront payment and potential milestone payments of up to $1.5 billion. Management has budgeted for research and development expenses of up to €2.5 billion in 2026 alone.
This investment comes as the company navigates a post-pandemic downturn. BioNTech forecasts a revenue decline of roughly 25% for 2026 to a range of €2.0 to €2.3 billion, reflecting the anticipated wind-down of its COVID-19 vaccine business. The planned BLA submission for BNT323 is the most tangible evidence that its oncology strategy is gaining concrete momentum. The company is also preparing for an organizational shift, with plans to expand its supervisory board with two oncology experts at its Annual General Meeting on May 15, signaling a long-term commitment to its new strategic direction.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from April 14 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 14.
BioNTech: Buy or sell? Read more here...
